Previous close | 26.58 |
Open | 26.58 |
Bid | 25.00 |
Ask | 35.00 |
Strike | 690.00 |
Expiry date | 2026-01-16 |
Day's range | 26.58 - 26.58 |
Contract range | N/A |
Volume | |
Open interest | 13 |
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
We’ve recently covered a list of 20 Biggest Publicly-Traded Biotech Companies based on market caps that you can visit here. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering $3.88 trillion by 2030. The […]